Christos Demponeras

Christos Demponeras

Auto-generated profile, based on publicly available information

Christos Demponeras

Athens University School of Nursing ICU, “Agioi Anargyroi” General Hospital, Kifisia, 14564 Athens, Greece

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2013 in Critical Care Research and Practice
Verified
Journal Article
Open access
PDF file
ETEVDOXIA TSIGOU
EVDOXIA TSIGOU
VPVasiliki Psallida
Vasiliki Psallida
CDChristos Demponeras
Christos Demponeras
EBEleni Boutzouka
Eleni Boutzouka
GBGeorge Baltopoulos
George Baltopoulos
Traditional diagnosis of acute kidney injury (AKI) depends on detection of oliguria and rise of serum creatinine level, which is an unreliable and delayed marker of kidney damage. Delayed diagnosis of AKI in the critically ill patient is related to increased morbidity and mortality, prolonged length of stay, and cost escalation. The discovery of a reliable biomarker for early diagnosis of AKI would be very helpful in facilitating early intervention, evaluating the effectiveness of therapy, and eventually reducing cost and improving outcome. Innovative technologies such as genomics and proteomics have contributed to the discovery of new biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), cystatin C (Cys C), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and liver-type fatty acid binding protein (L-FABP). The current status of the most promising of these novel AKI biomarkers, including NGAL, Cys C, KIM-1, L-FABP, and IL-18, is reviewed.

4 September 2012 in International Journal of Inflammation
Verified
Journal Article
Open access
PDF file
NKNikolaos Kafkas
Nikolaos Kafkas
CDChristos Demponeras
Christos Demponeras
FZFilitsa Zoubouloglou
Filitsa Zoubouloglou
LSLoukia Spanou
Loukia Spanou
DBDimitrios Babalis
Dimitrios Babalis
Konstantinos MakrisKonstantinos Makris
Konstantinos Makris
Background. Atherosclerosis is a chronic inflammatory disease and the acute clinical manifestations represent acute on chronic inflammation. Neutrophil gelatinase-associated lipocalin (NGAL) is found in the granules of human neutrophils, with many diverse functions. The aim of this study was to evaluate the hypothesis that levels NGAL in blood may reflect the inflammatory process in various stages of coronary artery disease. Methods. We studied 140 patients, with SA 40, UA 35, NSTEMI 40, and STEMI 25, and 20 healthy controls. Serum NGAL was measured upon admission and before coronary angiography. Results. Significant differences were observed in median serum-NGAL(ng/mL) between patients with SA (79.23 (IQR, 37.50100.32)), when compared with UA (108.00 (68.34177.59)), NSTEMI (166.49 (109.24247.20)), and STEMI (178.63 (111.18305.92)) patients and controls (50.31 (44.3069.78)) with significant incremental value from SA to STEMI. We observed a positive and significant correlation between serum-NGAL and hs-CRP (spearman coefficient rho = 0.685, 𝑃<0.0001) as well as with neutrophil counts (r = 0.511, 𝑃<0.0001). Conclusions. In patients with coronary artery disease serum levels of NGAL increase and reflect the degree of inflammatory process. In patients with acute coronary syndromes, serum levels of NGAL have high negative predictive value and reflecting the inflammatory status could show the severity of coronary clinical syndrome.